Caribou Biosciences

Caribou Biosciences is a leading biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. Caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. Forbes Magazine has called Cas9 the protein that "could change biotech forever" and the New York Times has noted that "the pace of new discoveries and applications is dizzying." Caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.

Company Growth (employees)
Type
Private
HQ
Berkeley, US
Founded
2011
Size (employees)
54 (est)
Caribou Biosciences was founded in 2011 and is headquartered in Berkeley, US

Key People/Management at Caribou Biosciences

Rachel E. Haurwitz

Rachel E. Haurwitz

Co-founder

Caribou Biosciences Office Locations

Caribou Biosciences has an office in Berkeley
Berkeley, US (HQ)
2929 7th St

Caribou Biosciences Financials and Metrics

Summary Metrics

Founding Date

2011

Total Funding

$44.5 m

Latest funding size

$30 m

Time since last funding

over 1 year

Investors

Caribou Biosciences's latest funding round in May 2016 was reported to be $30 m. In total, Caribou Biosciences has raised $44.5 m

Caribou Biosciences's Web-traffic and Trends

Caribou Biosciences Online and Social Media Presence

Caribou Biosciences Company Life and Culture

You may also be interested in